Detalles de la búsqueda
1.
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
Ann Rheum Dis
; 77(5): 658-666, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29483080
2.
Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.
Rheumatol Int
; 37(2): 213-218, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28012023
3.
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15â mg may be overcome with subcutaneous administration.
Ann Rheum Dis
; 73(8): 1549-51, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24728329
4.
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.
Ann Rheum Dis
; 73(12): 2174-7, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24972708
5.
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.
Am J Gastroenterol
; 107(3): 379-86, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22186979
6.
Response to: 'is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?' by Fleishman and Yazici.
Ann Rheum Dis
; 73(9): e55, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24962874
7.
Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
J Rheumatol Suppl
; 81: 4-30; quiz 31-4, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19193621
8.
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Curr Med Res Opin
; 22(1): 185-98, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16393444
9.
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Curr Med Res Opin
; 22(1): 169-83, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16393443
10.
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Drugs Aging
; 23(2): 167-78, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16536638
11.
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Semin Arthritis Rheum
; 45(1): 28-34, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25895697
12.
Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.
Drugs
; 64(22): 2493-501, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15516150
13.
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
J Rheumatol
; 39(7): 1326-33, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22589265
14.
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries.
J Rheumatol
; 38(1): 21-8, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20952478
15.
Integrated safety in tocilizumab clinical trials.
Arthritis Res Ther
; 13(5): R141, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21884601
16.
Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
J Rheumatol
; 38(7): 1273-81, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21572150
17.
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.
Arthritis Care Res (Hoboken)
; 63(3): 373-82, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20957659
18.
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
J Rheumatol
; 38(6): 990-6, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21362764
19.
Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications.
Am J Manag Care
; 16(9 Suppl): S243-8, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21517637
20.
Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial.
Arthritis Rheum
; 60(11): 3207-16, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19877047